药学专业硕士研究生导师-廖德华

药学学术硕士研究生导师—廖德华

一、基本情况

廖德华，男，1987年11月出生，博士，副主任药师，硕士研究生导师。2013年毕业于中南大学湘雅医学院，毕业后一直就职于湖南省肿瘤医院药学部。现担任湖南省肿瘤医院药学部副主任（分管临床药学及科教研），湖南省肿瘤医院临床药学教研室副主任。社会兼职：湖南省药学会理事、中国抗癌协会肿瘤临床药学专委会青委、中国药理学会TDM专委会青委、湖南省抗癌协会肿瘤药学专委会秘书、湖南省抗癌协会肿瘤精准治疗专委会委员、湖南省国际医学交流促进会肺癌专委会常委。

主要研究方向：肿瘤精准治疗及个体化给药、新型抗肿瘤药物毒副反应防治及机制研究、肿瘤耐药机制研究

二、教学与科研情况

主持的科研课题：

(1)国家自然科学基金青年基金，81603206，NSCLC患者厄洛替尼代谢酶及转运体基因多态性影响个体化治疗的群体PK/PD研究，2017.01-2019.12,17.3万元，主持，已结题。

(2) 湖南省自然科学基金,科卫联合, 2021JJ70025, 基于keap1-Nrf2-ARE 自噬轴探讨姜黄素拮抗多柔比星诱导神经毒性的分子机制, 2021-01至2023-12, 5.0 万元,在研,主持。

(3) 长沙市科技局, 长沙市科技计划项目, kq2004129, 丁苯酞在对抗多柔比星诱导的神经毒性中的作用及其分子机制研究, 2020-09 至 2022-08, 5.0 万元, 结题,主持。

(4) 湖南省医学会, 湖南省医学会医学科研基金临床药学项目, HMA202001005,
基于药代动力学特征探索厄洛替尼诱导的快速耐药机制, 2021-01 至 2023-01,
10.0 万元, 结题, 主持。
(5) 湖南省卫健委, 湖南省卫生计生委科研计划课题项目, B20180252, NSCLC 患者厄洛替尼代谢酶及转运体基因多态性导致的耐药及群体 PK/PD 研究, 2018-01至 2020-12, 1.2 万元, 结题, 主持。

第一作者及通讯作者发表的论文：

1.Dehua Liao,Yujin Guo,Daxiong Xiang,Ruili Dang,Pengfei Xu,Hualin Cai,Lizhi Cao,Pei Jiang. Dysregulation of neuregulin-1/erbB signaling in the hippocampus of rats after administration of doxorubicin. Drug Des Devel Ther . 2018 12:231-239.

2.Dehua Liao,Daxiong Xiang,Ruili Dang,Pengfei Xu,Jiemin Wang,Wenxiu Han,Yingzhou Fu,Dunwu Yao,Lizhi Cao,Pei Jiang. Neuroprotective Effects of dl-3-n-Butylphthalide against Doxorubicin-Induced Neuroinflammation, Oxidative Stress, Endoplasmic Reticulum Stress, and Behavioral Changes. Oxid Med Cell Longev . 2018:9125601.

3.Mengqi Yang,Ruili Dang,Pengfei Xu,Yujin Guo,Wenxiu Han,Dehua Liao,Pei Jiang. Dl-3-n-Butylphthalide improves lipopolysaccharide-induced depressive-like behavior in rats: involvement of Nrf2 and NF-κB pathways. Psychopharmacology (Berl) . 2018;5(9):2573-2585.

4.Dehua Liao,Chen Zhang,Ni Liu,Lizhi Cao,Changshui Wang,Qingyan Feng,Dunwu Yao,Minghui Long,Pei Jiang. Involvement of neurotrophic signaling in doxorubicin‑induced cardiotoxicity. Exp Ther Med . 2020;19(2):1129-1135. 

5.Dehua Liao,Yun Chen,Yujin Guo,Changshui Wang,Ni Liu,Qian Gong,Yingzhou Fu,Yilan Fu,Lizhi Cao,Dunwu Yao,Pei Jiang. Salvianolic Acid B Improves Chronic Mild Stress-Induced Depressive Behaviors in Rats: Involvement of AMPK/SIRT1 Signaling Pathway. J Inflamm Res . 2020, 13:195-206. 

6.Dehua Liao,Zhigang Liu,Yongchang Zhang,Ni Liu,Dunwu Yao,Lizhi Cao,Yun Chen,Yilan Fu,Nong Yang,Daxiong Xiang. Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor– Mutated Non-Small Cell Lung Cancer Patients. Front Pharmacol . 2020;11:664.

7.Dehua Liao,Dunwu Yao,Ni Liu,Lizhi Cao,Daxiong Xiang,Nong Yang,Yongchang Zhang,Wenjuan Jiang,Chunhua Zhou. Correlation of plasma erlotinib trough concentration with skin rash in Chinese NSCLC patients harboring exon 19 deletion mutation.  Cancer Chemother Pharmacol . 2018; 82(3):551-559. 

8.Dehua Liao,Lun Yu,Dangang Shangguan,Yongchang Zhang,Bowen Xiao,Ni Liu,Nong Yang. Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ ALK-TKIs and ICIs in Non–Small Cell Lung Cancer. Front Pharmacol . 2022; 13:905947.

9.Dehua Liao,Xinyi Liu,Wei Dai,Tiantian Tang,Ge Ou,Kai Zhang,Meng Han,Rongrong Kang,Sufang Yang,Daxiong Xiang. N-trimethyl chitosan (TMC)-modified microemulsions for improved oral bioavailability of puerarin: preparation and evaluation. Drug Deliv . 2015;22(4):516-21. 

10.Ting Yan, Lun Yu, Dangang Shangguan, Wei Li, Ni Liu, Yun Chen, Yilan Fu, Jingyi Tang, Dehua Liao. Advances in pharmacokinetics and pharmacodynamics of PD-1/ PD-L1 inhibitors. Int Immunopharmacol. 2023;115:109638.

11.Dehua Liao, Dangang Shangguan, Dunwu Yao, Qing Zhu, Lizhi Cao, Minghui Long, Yi Wu, Daxiong Xiang, Nong Yang. Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma. Protein Pept Lett. 2018;25(6):528-533. 

招生方向：临床药学、药理学、药剂学

长期欢迎对科研具有浓厚兴趣的本科生加入课题组！

联系方式：15802562025，liaodehua1125@126.com